Efficacy and tolerability of a low dose weekly paclitaxel, carboplatin and cetuximab ( PCC ) regimen for metastatic or unresectable head and neck squamous cell carcinomas
Clinical Otolaryngology · 2023
DOI: 10.1111/coa.14091 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Otolaryngology, 2023. Verfasst von Margaret Locke und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Zucker School of Medicine at Hofstra/Northwell, Manhasset, New York, USA. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Head and Neck Neoplasms, Squamous Cell Carcinoma of Head and Neck. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 10 Literaturangaben. Gefördert von: Institutional Review Board.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Zucker School of Medicine at Hofstra/Northwell, Manhasset, New York, USA.
- Office of Academic Affairs, Northwell Health, Manhasset, New York, USA.
- Monter Cancer Center, Northwell Health, Manhasset, New York, USA.
ORCID-Profile: Margaret Locke, Nina Kohn, Nagashree Seetharamu
Förderung
- Institutional Review Board
Zitieren
APA
Locke, M., Kohn, N., & Seetharamu, N. (2023). Efficacy and tolerability of a low dose weekly paclitaxel, carboplatin and cetuximab ( PCC ) regimen for metastatic or unresectable head and neck squamous cell carcinomas. Clinical Otolaryngology. https://doi.org/10.1111/coa.14091
Vancouver
Locke M, Kohn N, Seetharamu N. Efficacy and tolerability of a low dose weekly paclitaxel, carboplatin and cetuximab ( PCC ) regimen for metastatic or unresectable head and neck squamous cell carcinomas. Clinical Otolaryngology. 2023. doi:10.1111/coa.14091
BibTeX
@article{Locke2023,
author = {Locke, Margaret and Kohn, Nina and Seetharamu, Nagashree},
title = {Efficacy and tolerability of a low dose weekly paclitaxel, carboplatin and cetuximab ( PCC ) regimen for metastatic or unresectable head and neck squamous cell carcinomas},
journal = {Clinical Otolaryngology},
year = {2023},
doi = {10.1111/coa.14091}
}
EUVIMED